Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.

Boerekamps, Anne

Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. [electronic resource] - The lancet. Gastroenterology & hepatology 04 2019 - 269-277 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

2468-1253

10.1016/S2468-1253(18)30414-X doi


Acute Disease
Administration, Oral
Adult
Amides
Antiviral Agents--administration & dosage
Belgium--epidemiology
Benzofurans--administration & dosage
Carbamates
Cyclopropanes
Drug Therapy, Combination--methods
Female
Genotype
Hepacivirus--drug effects
Hepatitis C--drug therapy
Humans
Imidazoles--administration & dosage
Incidence
Male
Middle Aged
Netherlands--epidemiology
Quinoxalines--administration & dosage
Sexually Transmitted Diseases--epidemiology
Sulfonamides
Sustained Virologic Response
Time Factors
Treatment Failure
Treatment Outcome